dipyridamole has been researched along with No-Reflow Phenomenon in 3 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
No-Reflow Phenomenon: Markedly reduced or absent REPERFUSION in an infarct zone following the removal of an obstruction or constriction of an artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "No previous study has assessed the possible role of dipyridamole for treatment of no-reflow during acute myocardial infarction (AMI)." | 5.14 | Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. ( Arrivi, A; Greco, C; Mangieri, E; Pasceri, V; Pelliccia, F; Placanica, A; Tanzilli, G, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanzilli, G | 1 |
| Greco, C | 1 |
| Pasceri, V | 1 |
| Pelliccia, F | 1 |
| Arrivi, A | 1 |
| Placanica, A | 1 |
| Mangieri, E | 1 |
| Gilchrist, IC | 1 |
| Grenz, A | 1 |
| Bauerle, JD | 1 |
| Dalton, JH | 1 |
| Ridyard, D | 1 |
| Badulak, A | 1 |
| Tak, E | 1 |
| McNamee, EN | 1 |
| Clambey, E | 1 |
| Moldovan, R | 1 |
| Reyes, G | 1 |
| Klawitter, J | 1 |
| Ambler, K | 1 |
| Magee, K | 1 |
| Christians, U | 1 |
| Brodsky, KS | 1 |
| Ravid, K | 1 |
| Choi, DS | 1 |
| Wen, J | 1 |
| Lukashev, D | 1 |
| Blackburn, MR | 1 |
| Osswald, H | 1 |
| Coe, IR | 1 |
| Nürnberg, B | 1 |
| Haase, VH | 1 |
| Xia, Y | 1 |
| Sitkovsky, M | 1 |
| Eltzschig, HK | 1 |
1 trial available for dipyridamole and No-Reflow Phenomenon
| Article | Year |
|---|---|
Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Angiography; Coronary Circul | 2010 |
2 other studies available for dipyridamole and No-Reflow Phenomenon
| Article | Year |
|---|---|
No-reflow: Still searching for that magic bullet.
Topics: Angioplasty, Balloon, Coronary; Coronary Circulation; Dipyridamole; Humans; Myocardial Infarction; N | 2010 |
Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.
Topics: Acute Kidney Injury; Adenosine; Animals; Cell Line; Chimerism; Dipyridamole; Equilibrative Nucleosid | 2012 |